【線上課程，請先報名】Targeting KRAS G12C in mCRC: From Science to Taiwan Practice

【線上課程，請先報名】Targeting KRAS G12C in mCRC: From Science to Taiwan Practice
時間：114年11月07日 (星期五) 19:00-20:30
主辦單位：中華民國大腸直腸外科醫學會
報名網址：報名11/07線上課程

本會醫師會員積分：5分
上線時間低於80分鐘，不提供積分。

Speaker: 張沛泓醫師
Targeting KRAS G12C in mCRC: From Biology to Current and Novel Treatment
Strategies
KRAS G12C mutations occur in about 3–4% of metastatic colorectal cancer (mCRC)
and are linked to poor prognosis and limited treatment options. The CodeBreaK 300
trial demonstrated that sotorasib 960 mg plus panitumumab significantly improved
objective response rate and showed a trend toward longer overall survival compared
with trifluridine/tipiracil plus bevacizumab, with a manageable safety profile.
This session will review the biological rationale for KRAS G12C inhibition, summarize
key findings from CodeBreaK 300, and discuss how sotorasib plus panitumumab is
shaping a new precision medicine era for patients with KRAS G12C–mutated mCRC.

Speaker: 張伸吉醫師
Real-World Clinical Experience in Taiwan: Lumakras Combined with Vectibix for
KRAS G12C MT mCRC
In Taiwan, this combination has recently received regulatory approval—the first in
the JAPAC region—marking a milestone in precision oncology. This presentation will
share real-world clinical experience from Taiwanese practice, including patient
profiles, treatment responses, and management of adverse events. Additionally,
insights from clinical trial participation and enrollment experience will be discussed,
focusing on multidisciplinary collaboration, patient selection, and biomarker testing
strategies.
Together, these experiences underscore how the Lumakras plus Vectibix
combination is transforming treatment paradigms for patients with KRAS
G12C–mutated mCRC, bridging global evidence and local clinical application.



↓↓↓網頁最下方，活動議程，請自行下載。↓↓↓

 

【附件下載】

• 1141107-線上課程TWN-510-1025-80010